Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of N9-GP vs Alprolix in Haemophilia B
NCT03075670Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of nonacog beta pegol in hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the factor IX activity-time curve from 0 to infinity dose-normalised to 50 IU/kg. Started Mar 2017; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03075670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075670.